BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 11464914)

  • 21. Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in Evi-1 transformed fibroblasts.
    Kilbey A; Stephens V; Bartholomew C
    Cell Growth Differ; 1999 Sep; 10(9):601-10. PubMed ID: 10511310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Downregulation of cyclin D1 alters cdk 4- and cdk 2-specific phosphorylation of retinoblastoma protein.
    Yu B; Lane ME; Pestell RG; Albanese C; Wadler S
    Mol Cell Biol Res Commun; 2000 Jun; 3(6):352-9. PubMed ID: 11032757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of p27Kip1 from cyclin E/cyclin-dependent kinase (CDK) 2 but not from cyclin D1/CDK4 complexes in cells transformed by polyamine biosynthetic enzymes.
    Ravanko K; Järvinen K; Paasinen-Sohns A; Hölttä E
    Cancer Res; 2000 Sep; 60(18):5244-53. PubMed ID: 11016654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TGF-beta 1 induces the cyclin-dependent kinase inhibitor p27Kip1 mRNA and protein in murine B cells.
    Kamesaki H; Nishizawa K; Michaud GY; Cossman J; Kiyono T
    J Immunol; 1998 Jan; 160(2):770-7. PubMed ID: 9551912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity.
    Berns K; Hijmans EM; Bernards R
    Oncogene; 1997 Sep; 15(11):1347-56. PubMed ID: 9315103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
    Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
    Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
    Rao S; Lowe M; Herliczek TW; Keyomarsi K
    Oncogene; 1998 Nov; 17(18):2393-402. PubMed ID: 9811471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes.
    Nahum A; Hirsch K; Danilenko M; Watts CK; Prall OW; Levy J; Sharoni Y
    Oncogene; 2001 Jun; 20(26):3428-36. PubMed ID: 11423993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Formation of p27-CDK complexes during the human mitotic cell cycle.
    Soos TJ; Kiyokawa H; Yan JS; Rubin MS; Giordano A; DeBlasio A; Bottega S; Wong B; Mendelsohn J; Koff A
    Cell Growth Differ; 1996 Feb; 7(2):135-46. PubMed ID: 8822197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens.
    Carroll JS; Swarbrick A; Musgrove EA; Sutherland RL
    Cancer Res; 2002 Jun; 62(11):3126-31. PubMed ID: 12036924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. pRb and Cdk regulation by N-(4-hydroxyphenyl)retinamide.
    Panigone S; Debernardi S; Taya Y; Fontanella E; Airoldi R; Delia D
    Oncogene; 2000 Aug; 19(35):4035-41. PubMed ID: 10962560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phenylacetate inhibits growth and modulates cell cycle gene expression in renal cancer cell lines.
    Franco OE; Onishi T; Umeda Y; Soga N; Wakita T; Arima K; Yanagawa M; Sugimura Y
    Anticancer Res; 2003; 23(2B):1637-42. PubMed ID: 12820434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.
    Orend G; Hunter T; Ruoslahti E
    Oncogene; 1998 May; 16(20):2575-83. PubMed ID: 9632134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased cdc2 and cdk2 kinase activity by retinoid X receptor gamma-mediated transcriptional down-regulation of the cyclin-dependent kinase inhibitor p21Cip1/WAF1 correlates with terminal differentiation of squamous cell carcinoma lines.
    Crowe DL; Shuler CF
    Cell Growth Differ; 1998 Aug; 9(8):619-27. PubMed ID: 9716179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell cycle-dependent phosphorylation of p27 cyclin-dependent kinase (Cdk) inhibitor by cyclin E/Cdk2.
    Morisaki H; Fujimoto A; Ando A; Nagata Y; Ikeda K; Nakanishi M
    Biochem Biophys Res Commun; 1997 Nov; 240(2):386-90. PubMed ID: 9388487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells.
    Gong J; Ammanamanchi S; Ko TC; Brattain MG
    Cancer Res; 2003 Jun; 63(12):3340-6. PubMed ID: 12810668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disruption of the actin cytoskeleton leads to inhibition of mitogen-induced cyclin E expression, Cdk2 phosphorylation, and nuclear accumulation of the retinoblastoma protein-related p107 protein.
    Reshetnikova G; Barkan R; Popov B; Nikolsky N; Chang LS
    Exp Cell Res; 2000 Aug; 259(1):35-53. PubMed ID: 10942577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1.
    Flørenes VA; Bhattacharya N; Bani MR; Ben-David Y; Kerbel RS; Slingerland JM
    Oncogene; 1996 Dec; 13(11):2447-57. PubMed ID: 8957087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The accumulation of cyclin-dependent kinase inhibitor p27kip1 is a primary response to staurosporine and independent of G1 cell cycle arrest.
    Nishi K; Schnier JB; Bradbury EM
    Exp Cell Res; 1998 Sep; 243(2):222-31. PubMed ID: 9743582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Posttranslational mechanisms contribute to the suppression of specific cyclin:CDK complexes by all-trans retinoic acid in human bronchial epithelial cells.
    Sueoka N; Lee HY; Walsh GL; Hong WK; Kurie JM
    Cancer Res; 1999 Aug; 59(15):3838-44. PubMed ID: 10447003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.